PURPOSE: The validity of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes to identify diagnoses of severe acute liver injury (SALI) is not well known. We examined the positive predictive values (PPVs) of hospital ICD-9-CM diagnoses in identifying SALI among health plan members in the Mini-Sentinel Distributed Database (MSDD) for patients without liver/biliary disease and for those with chronic liver disease (CLD). METHODS: We selected random samples of members (149 without liver/biliary disease; 75 with CLD) with a principal hospital diagnosis suggestive of SALI (ICD-9-CM 570, 572.2, 572.4, 572.8, 573.3, 573.8, or V42.7) in the MSDD (2009-2010). Medical records were reviewed by hepatologists to confirm SALI events. PPVs of codes and code combinations for confirmed SALI were determined by CLD status. RESULTS: Among 105 members with available records and no liver/biliary disease, SALI was confirmed in 26 (PPV, 24.7%; 95%CI, 16.9-34.1%). Combined hospital diagnoses of acute hepatic necrosis (570) and liver disease sequelae (572.8) had high PPV (100%; 95%CI, 59.0-100%) and identified 7/26 (26.9%) events. Among 46 CLD members with available records, SALI was confirmed in 19 (PPV, 41.3%; 95%CI, 27.0-56.8%). Acute hepatic necrosis (570) or hepatorenal syndrome (572.4) plus any other SALI code had a PPV of 83.3% (95%CI, 51.6-97.9%) and identified 10/19 (52.6%) events. CONCLUSIONS: Most individual hospital ICD-9-CM diagnoses had low PPV for confirmed SALI events. Select code combinations had high PPV but did not capture all events.
PURPOSE: The validity of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes to identify diagnoses of severe acute liver injury (SALI) is not well known. We examined the positive predictive values (PPVs) of hospital ICD-9-CM diagnoses in identifying SALI among health plan members in the Mini-Sentinel Distributed Database (MSDD) for patients without liver/biliary disease and for those with chronic liver disease (CLD). METHODS: We selected random samples of members (149 without liver/biliary disease; 75 with CLD) with a principal hospital diagnosis suggestive of SALI (ICD-9-CM 570, 572.2, 572.4, 572.8, 573.3, 573.8, or V42.7) in the MSDD (2009-2010). Medical records were reviewed by hepatologists to confirm SALI events. PPVs of codes and code combinations for confirmed SALI were determined by CLD status. RESULTS: Among 105 members with available records and no liver/biliary disease, SALI was confirmed in 26 (PPV, 24.7%; 95%CI, 16.9-34.1%). Combined hospital diagnoses of acute hepatic necrosis (570) and liver disease sequelae (572.8) had high PPV (100%; 95%CI, 59.0-100%) and identified 7/26 (26.9%) events. Among 46 CLD members with available records, SALI was confirmed in 19 (PPV, 41.3%; 95%CI, 27.0-56.8%). Acute hepatic necrosis (570) or hepatorenal syndrome (572.4) plus any other SALI code had a PPV of 83.3% (95%CI, 51.6-97.9%) and identified 10/19 (52.6%) events. CONCLUSIONS: Most individual hospital ICD-9-CM diagnoses had low PPV for confirmed SALI events. Select code combinations had high PPV but did not capture all events.
Authors: Raúl J Andrade; M Isabel Lucena; M Carmen Fernández; Gloria Pelaez; Ketevan Pachkoria; Elena García-Ruiz; Beatriz García-Muñoz; Rocio González-Grande; Angeles Pizarro; José Antonio Durán; Manuel Jiménez; Luis Rodrigo; Manuel Romero-Gomez; José María Navarro; Ramón Planas; Joan Costa; Africa Borras; Aina Soler; Javier Salmerón; Rafael Martin-Vivaldi Journal: Gastroenterology Date: 2005-08 Impact factor: 22.682
Authors: Karin Martin; Bernard Bégaud; Philippe Latry; Ghada Miremont-Salamé; Annie Fourrier; Nicholas Moore Journal: Br J Clin Pharmacol Date: 2004-01 Impact factor: 4.335
Authors: Jeanette M Tetrault; Janet P Tate; E Jennifer Edelman; Adam J Gordon; Vincent Lo Re; Joseph K Lim; David Rimland; Joseph Goulet; Stephen Crystal; Julie R Gaither; Cynthia L Gibert; Maria C Rodriguez-Barradas; Lynn E Fiellin; Kendall Bryant; Amy C Justice; David A Fiellin Journal: J Subst Abuse Treat Date: 2016-06-06
Authors: Vibha C A Desai; Scott C Quinlan; Anne C Deitz; Jinghua He; Crystal N Holick; Stephan Lanes Journal: J Neurooncol Date: 2017-07-17 Impact factor: 4.130
Authors: A Ruigómez; R Brauer; L A García Rodríguez; C Huerta; G Requena; M Gil; Francisco de Abajo; G Downey; A Bate; M Feudjo Tepie; M de Groot; R Schlienger; R Reynolds; O Klungel Journal: Eur J Clin Pharmacol Date: 2014-07-29 Impact factor: 2.953
Authors: Loreen Straub; Joshua J Gagne; Judith C Maro; Michael D Nguyen; Nicolas Beaulieu; Jeffrey S Brown; Adee Kennedy; Margaret Johnson; Adam Wright; Li Zhou; Shirley V Wang Journal: Drug Saf Date: 2019-09 Impact factor: 5.606
Authors: Vincent Lo Re; Dena M Carbonari; Kimberly A Forde; David Goldberg; James D Lewis; Kevin Haynes; Kimberly B F Leidl; Rajender K Reddy; Jason Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley Journal: Pharmacoepidemiol Drug Saf Date: 2015-04-10 Impact factor: 2.890
Authors: Vincent Lo Re; Dena M Carbonari; James D Lewis; Kimberly A Forde; David S Goldberg; K Rajender Reddy; Kevin Haynes; Jason A Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley Journal: Am J Med Date: 2015-11-17 Impact factor: 4.965